血管紧张素转换酶基因I/D多态性与埃他卡林抗高血压临床疗效之间的相关性

Correlation between ACE gene I/D polymorphism and clinical efficacy of iptakalim in Chinese Han hypertensive population

目的:研究汉族高血压人群血管紧张素转换酶(angiotensin converting enzyme,ACE)基因插入/缺失(I/D)多态性与埃他卡林临床疗效的关系。方法:对162例汉族原发性高血压(EH)患者给予埃他卡林8周治疗,并进行ACE基因I/D多态性分析。结果:162例汉族高血压患者ACE基因I/D多态性分型结果为:II∶ID∶DD(0.401∶0.463∶0.136)。埃他卡林治疗前收缩压(SBP)和舒张压(DBP)分别是(153±13)mm Hg和(100±4)mm Hg。各基因型组患者在药物治疗前SBP和DBP的特点是DD基因型组的SBP显著高于II和ID基因型组(P<0.05),而3种基因型组的DBP比较相近(P>0.05)。治疗后SBP和DBP分别是(142±13)mm Hg和(89±9)mm Hg。治疗后II基因型组患者的ΔDBP显著大于ID组的ΔDBP(P<0.05)。治疗后血压较治疗前血压降低(P<0.001)。162例汉族高血压患者埃他卡林治疗8周后临床有效率为66.67%。II基因型组的总降压有效率(75.38%)比ID基因型组的总降压有效率(58.67%)高(P<0.05)。结论:埃他卡林是新型有效降压药物,II基因型患者对埃他卡林的降压反应较好。

AIM：To study the correlation between angiotensin-converting enzyme（ACE） gene insertion/deletion（I/D） polymorphism and the clinical efficacy of iptakalim in a Chinese Han hypertensive population. METHODS：The ACE I/D polymorphism of 162 Chinese Han hypertensive patients treated with iptakalim for 8 weeks was determined by the polymerase chain reaction technique.RESULTS：Among the 162 cases of hypertensive patients,the frequencies of II,ID,and DD were 40.1%,46.3%,and 13.6%,respectively.The pretreatment SBP and DBP were（153±13） mm Hg and（100±4） mm Hg,respectively.The pretreatment DBP were not different in the three groups,while the pretreatment SBP were larger in patients with the DD genotype than those with the II and ID genotypes（P0.05）.The posttreatment SBP and DBP were（142±13） mm Hg and（89±9） mm Hg,respectively.The changes of SBP and DBP by iptakalim were significant（P0.001）.The posttreatment SBP were similar in the three groups,while a greater decrease in DBP was observed in patients with the II genotype than those with the ID genotype（P0.05）.The clinical efficacy was 66.67% after iptakalim administration in 162 patients.The clinical efficacy of the II genotype group（75.38%） was higher than that of the ID genotype group（58.67%）（P0.05）.CONCLUSION：Iptakalim is a new and effective antihypertensive drug.The patients with the genotype II have better clinical efficacy.